LENZ Therapeutics, Inc. (LENZ) Institutional Ownership

Ownership Summary

LENZ Therapeutics, Inc. (NASDAQ:LENZ) currently has 29 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• LENZ Therapeutics saw its institutional ownership percentage fell to 14.8% in December 2025 from 102.9% in September 2025.
• Quarterly data indicates a 46.41% shift in institutional share volume, and the annual owner count reflects a decrease of 69.47%.
• Of these 29 institutional investors, 16 increased their holdings in LENZ Therapeutics, while 6 of them reduced positions, and 7 investors maintained their exposure.
• The aggregate institutional position in LENZ Therapeutics now stands at 4.19Mn shares as of December 2025, after investors increased their holdings (up by 1.33Mn shares quarter on quarter which is down 15.57Mn shares year over year).
• As of December 31, 2025, UBS Group AG held LENZ Therapeutics's largest shareholding position with over 1.57Mn shares, representing 5.55% of total outstanding shares.
• Among the most significant buyers of LENZ Therapeutics during December 2025 were C WorldWide Group Holding A/S (500.00K), UBS Group AG (370.12K), Aberdeen Group plc (358.71K), Sovran Advisors, LLC (53.21K), DnB Asset Management AS (19.16K).
• Leading sellers of LENZ Therapeutics stock in December 2025 included VANGUARD GROUP INC (9.08K), China Universal Asset Management Co., Ltd. (2.90K), SBI Securities Co., Ltd. (1.50K), CWM, LLC (143), GAMMA Investing LLC (58).
• The top 10 institutional holders of LENZ Therapeutics for the quarter ending December 2025 included UBS Group AG (1.57Mn), VANGUARD GROUP INC (1.32Mn), C WorldWide Group Holding A/S (500.00K), Aberdeen Group plc (489.43K), Sovran Advisors, LLC (160.13K), KESTRA PRIVATE WEALTH SERVICES, LLC (27.30K), HARBOR CAPITAL ADVISORS, INC. (23.92K), DnB Asset Management AS (19.16K), State of Alaska, Department of Revenue (19.16K), KELLEHER FINANCIAL ADVISORS (17.02K).